{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T03:29:01Z","timestamp":1783567741137,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T00:00:00Z","timestamp":1750032000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biohaven Pharmaceuticals Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40120-025-00771-5","type":"journal-article","created":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T22:04:33Z","timestamp":1750025073000},"page":"1609-1625","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Development and Validation of PARCOMS Composite Scales for Assessing Disease Progression and Treatment Effects in Parkinson\u2019s Disease"],"prefix":"10.1007","volume":"14","author":[{"given":"Gil","family":"L\u2019Italien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basia","family":"Rogula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7389-3354","authenticated-orcid":false,"given":"Michele","family":"Potashman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel P.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Kozauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"O\u2019Keefe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Korol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Crabtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Coric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Dubow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana S.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,16]]},"reference":[{"key":"771_CR1","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1016\/S1474-4422(1109)70291-70291","volume":"8","author":"W Maetzler","year":"2009","unstructured":"Maetzler W, Liepelt I, Berg D. Progression of Parkinson\u2019s disease in the clinical phase: potential markers. Lancet Neurol. 2009;8:1158\u201371. https:\/\/doi.org\/10.1016\/S1474-4422(1109)70291-70291. (ResearchSupport,Non-U.S.Gov'tReview).","journal-title":"Lancet Neurol"},{"key":"771_CR2","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1001\/jama.2019.22360","volume":"323","author":"MJ Armstrong","year":"2020","unstructured":"Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323:548\u201360. https:\/\/doi.org\/10.1001\/jama.2019.22360.","journal-title":"JAMA"},{"key":"771_CR3","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1212\/WNL.0000000000012868","volume":"97","author":"T Pringsheim","year":"2021","unstructured":"Pringsheim T, Day GS, Smith DB, et al. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary. Neurology. 2021;97:942\u201357. https:\/\/doi.org\/10.1212\/WNL.0000000000012868.","journal-title":"Neurology"},{"key":"771_CR4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4103\/AOMD.AOMD_33_19","volume":"3","author":"J Pitton Rissardo","year":"2020","unstructured":"Pitton Rissardo J, Fornari CA. Parkinson\u2019s disease rating scales: a literature review. Ann Mov Disord. 2020;3:3\u201322. https:\/\/doi.org\/10.4103\/AOMD.AOMD_33_19.","journal-title":"Ann Mov Disord"},{"key":"771_CR5","doi-asserted-by":"publisher","first-page":"21171","DOI":"10.1038\/s41598-024-71555-4","volume":"14","author":"JR Mammen","year":"2024","unstructured":"Mammen JR, Tyo M, Cadorette J, et al. Understanding what aspects of Parkinson\u2019s disease matter most to patients and families. Sci Rep. 2024;14:21171. https:\/\/doi.org\/10.1038\/s41598-024-71555-4.","journal-title":"Sci Rep"},{"key":"771_CR6","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1212\/WNL.0000000000004743","volume":"89","author":"SA Schobel","year":"2017","unstructured":"Schobel SA, Palermo G, Auinger P, et al. Motor, cognitive, and functional declines contribute to a single progressive factor in early HD. Neurology. 2017;89:2495\u2013502.","journal-title":"Neurology"},{"key":"771_CR7","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1136\/jnnp-2015-312383","volume":"87","author":"J Wang","year":"2016","unstructured":"Wang J, Logovinsky V, Hendrix SB, et al. ADCOMS: a composite clinical outcome for prodromal Alzheimer\u2019s disease trials. J Neurol Neurosurg Psychiatry. 2016;87:993\u20139. https:\/\/doi.org\/10.1136\/jnnp-2015-312383.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"771_CR8","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40120-024-00661-2","volume":"21","author":"SP Dickson","year":"2024","unstructured":"Dickson SP, Mallinckrodt CH, Rogula B, et al. Development of a General Composite Scale (GENCOMS) for Progressive Neurodegenerative Diseases and Implications for the Assessment of Disease-Modifying Therapies. Neurol Ther. 2024;21:47. https:\/\/doi.org\/10.1007\/s40120-024-00661-2.","journal-title":"Neurol Ther"},{"issue":"1259\u20131264","key":"771_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/mds.28489","volume":"36","author":"C Estevez-Fraga","year":"2021","unstructured":"Estevez-Fraga C, Scahill RI, Durr A, et al. Composite UHDRS correlates with progression of imaging biomarkers in Huntington\u2019s disease. Mov Disord. 2021;36(1259\u20131264):12. https:\/\/doi.org\/10.1002\/mds.28489. (Epub 22021 Jan 28420. Research Support, Non-U.S. Gov't).","journal-title":"Mov Disord"},{"key":"771_CR10","first-page":"024","volume":"7","author":"G L'Italien","year":"2024","unstructured":"L\u2019Italien G, Popoff E, Rogula B, et al. Development and validation of SCACOMS, a composite scale for assessing disease progression and treatment effects in spinocerebellar ataxia. Cerebellum. 2024;7:024\u201301697.","journal-title":"Cerebellum"},{"key":"771_CR11","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370. https:\/\/doi.org\/10.1002\/mds.22340.","journal-title":"Mov Disord"},{"key":"771_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.pneurobio.2011.09.005","volume":"95","author":"PPM Initiative","year":"2011","unstructured":"Initiative PPM. The Parkinson Progression Marker Initiative (PPMI). Progress Neurobiol. 2011;95:629\u201335. https:\/\/doi.org\/10.1016\/j.pneurobio.2011.09.005.","journal-title":"Progress Neurobiol"},{"key":"771_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/alzrt127","volume":"4","author":"SB Hendrix","year":"2012","unstructured":"Hendrix SB. Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time. Alzheimer\u2019s Res Ther. 2012;4:1\u20137.","journal-title":"Alzheimer's Res Ther"},{"key":"771_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.medcli.2012.11.028","volume":"142","author":"J Shi","year":"2014","unstructured":"Shi J, Liu J, Qu Q. Handedness and dominant side of symptoms in Parkinson\u2019s disease. Med Clin. 2014;142:141\u20134. https:\/\/doi.org\/10.1016\/j.medcli.2012.11.028.","journal-title":"Med Clin"},{"key":"771_CR15","doi-asserted-by":"publisher","first-page":"100074","DOI":"10.1016\/j.prdoa.2020.100074","volume":"3","author":"M Dumican","year":"2020","unstructured":"Dumican M, Watts C. Self-perceptions of speech, voice, and swallowing in motor phenotypes of Parkinson\u2019s disease. Clin Park Relat Disord. 2020;3:100074. https:\/\/doi.org\/10.1016\/j.prdoa.2020.100074.","journal-title":"Clin Park Relat Disord"},{"key":"771_CR16","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1044\/2021_jslhr-21-00216","volume":"65","author":"CR Watts","year":"2022","unstructured":"Watts CR, Zhang Y. Progression of self-perceived speech and swallowing impairment in early stage Parkinson\u2019s disease: longitudinal analysis of the unified Parkinson\u2019s Disease Rating Scale. J Speech Lang Hear Rese JSLHR. 2022;65:146\u201358. https:\/\/doi.org\/10.1044\/2021_jslhr-21-00216.","journal-title":"J Speech Lang Hear Rese JSLHR"},{"key":"771_CR17","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1212\/01.wnl.0000268695.63392.10","volume":"69","author":"B Ravina","year":"2007","unstructured":"Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology. 2007;69:342\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000268695.63392.10.","journal-title":"Neurology"},{"key":"771_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1002\/mds.28884","volume":"37","author":"S Zolfaghari","year":"2022","unstructured":"Zolfaghari S, Thomann AE, Lewandowski N, et al. Self-Report versus clinician examination in early Parkinson\u2019s disease. Mov Disord. 2022;37:585\u201397. https:\/\/doi.org\/10.1002\/mds.28884.","journal-title":"Mov Disord"},{"key":"771_CR19","doi-asserted-by":"publisher","first-page":"1264143","DOI":"10.3389\/fnagi.2023.1264143","volume":"15","author":"S Li","year":"2023","unstructured":"Li S, Lin Q, Bao Y, et al. Impaired night-time mobility in patients with Parkinson\u2019s disease: a systematic review. Front Aging Neurosci. 2023;15:1264143. https:\/\/doi.org\/10.3389\/fnagi.2023.1264143.","journal-title":"Front Aging Neurosci"},{"key":"771_CR20","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.parkreldis.2015.11.003","volume":"23","author":"J Sringean","year":"2016","unstructured":"Sringean J, Taechalertpaisarn P, Thanawattano C, et al. How well do Parkinson\u2019s disease patients turn in bed? Quantitative analysis of nocturnal hypokinesia using multisite wearable inertial sensors. Parkinsonism Related Disord. 2016;23:10\u20136. https:\/\/doi.org\/10.1016\/j.parkreldis.2015.11.003.","journal-title":"Parkinsonism Related Disord"},{"key":"771_CR21","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1001\/archneur.61.12.1906","volume":"61","author":"D Aarsland","year":"2004","unstructured":"Aarsland D, Andersen K, Larsen JP, et al. The rate of cognitive decline in Parkinson disease. Arch Neurol. 2004;61:1906\u201311. https:\/\/doi.org\/10.1001\/archneur.61.12.1906.","journal-title":"Arch Neurol"},{"issue":"Suppl 11","key":"771_CR22","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/mds.20460","volume":"20","author":"CH Adler","year":"2005","unstructured":"Adler CH. Nonmotor complications in Parkinson\u2019s disease. Mov Disord. 2005;20(Suppl 11):S23-29. https:\/\/doi.org\/10.1002\/mds.20460.","journal-title":"Mov Disord"},{"key":"771_CR23","doi-asserted-by":"publisher","unstructured":"Picillo M, Palladino R, Barone P, et al. The PRIAMO study: urinary dysfunction as a marker of disease progression in early Parkinson's disease. European journal of neurology 2017; 24: 788\u2013795. 2017\/04\/21. https:\/\/doi.org\/10.1111\/ene.13290.","DOI":"10.1111\/ene.13290"},{"key":"771_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s12883-018-1151-z","volume":"18","author":"F Valentino","year":"2018","unstructured":"Valentino F, Bartolotta TV, Cosentino G, et al. Urological dysfunctions in patients with Parkinson\u2019s disease: clues from clinical and non-invasive urological assessment. BMC Neurol. 2018;18:148. https:\/\/doi.org\/10.1186\/s12883-018-1151-z.","journal-title":"BMC Neurol"},{"key":"771_CR25","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2024.64","author":"SP Dickson","year":"2024","unstructured":"Dickson SP, Haaland B, Mallinckrodt CH, et al. \u201cTime Saved\u201d calculations to improve decision-making in progressive disease studies. J Prev Alzheimer\u2019s Dis. 2024. https:\/\/doi.org\/10.14283\/jpad.2024.64.","journal-title":"J Prev Alzheimer\u2019s Dis"},{"key":"771_CR26","doi-asserted-by":"publisher","first-page":"595","DOI":"10.14283\/jpad.2023.50","volume":"10","author":"SP Dickson","year":"2023","unstructured":"Dickson SP, Wessels AM, Dowsett SA, et al. \u201cTime Saved\u201d as a demonstration of clinical meaningfulness and illustrated using the donanemab TRAILBLAZER-ALZ study findings. J Prev Alzheimer\u2019s Dis. 2023;10:595\u20139. https:\/\/doi.org\/10.14283\/jpad.2023.50.","journal-title":"J Prev Alzheimer's Dis"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-025-00771-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-025-00771-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T19:32:40Z","timestamp":1757187160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-025-00771-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,16]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["771"],"URL":"https:\/\/doi.org\/10.1007\/s40120-025-00771-5","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,16]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gil L'Italien, Michele Potashman, and Vlad Coric are employees of Biohaven Pharmaceuticals, Inc. Nick Kozauer was an employee of Biohaven Pharmaceuticals, Inc. at the time of study completion, and currently works for Clintrex Research Corporation. Basia Rogula, Lauren Powell, Ellen Korol, Madeleine Crabtree, and Fernanda Nagase are employees of Broadstreet HEOR which was contracted by Biohaven Pharmaceuticals, Inc for the conduct of this study. Samuel P. Dickson, Patrick O\u2019Keefe, and Suzanne Hendrix are employees of Pentara Corporation which was contracted by Biohaven Pharmaceuticals, Inc for the conduct of this study. Jordan Dubow and Liana S. Rosenthal received consulting fees from Biohaven Pharmaceuticals, Inc. Dr. Rosenthal is an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine. Dr. Rosenthal engaged in this research as a private consultant or advisor and not in her capacity as a Johns Hopkins faculty member. Dr. Rosenthal was compensated for the consulting or advising service in income.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethics approval was not required for this study as it did not involve the recruitment of subjects. Data used in this study were de-identified and publicly available.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}